there are only a few changes necessary to make it function even better. And another 50% felt that it functions quite well on the whole, and there are only a few changes necessary to make it function even better. Assessment using a validated disease activity measure for SLE was regularly performed by 66.7% of the respondents and they all used Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) with 2 responders using both SLEDAI and British Isles Lupus Activity Group (BILAG). Eighty-eight percent responded that mycophenolate mofetil (MMF) was approved for treatment of SLE in their country with 72.2% responding that it was reimbursed. It was 83.3% and 94.4% for intravenous (IV) cyclophosphamide, 50.0% and 80.0% for tacrolimus, 72.2% and 5.6% for belimumab and 33.3% and 33.3% for rituximab, respectively. MMF was most commonly used in induction therapy for lupus nephritis (40.0%, IQR 25.0 65.0), followed by IV cyclophosphamide National Institute of Health (NIH) protocol (20.0%, IQR 4.0 40.0), IV cyclophosphamide Euro-Lupus Nephritis Trial protocol (15.0%, IQR 5.0 27.5), tacrolimus plus MMF (2.5%, IQR 0.0 8.8), tacrolimus (0.0%, IQR 0.0 5.0), and oral cyclophosphamide (0.0%, IQR 0.0 2.0).

Conclusions There are disparities influencing the management of SLE in Asia and Pacific countries. Some of the recommended treatments for SLE are not approved and not reimbursed for management of SLE in some Asia and Pacific countries.

Funding Source(s): None

260

MIR-326 PROMOTES RENAL INJURY IN MURINE LUPUS NEPHRITIS

¹Yuan Xia*, ¹Xuan Fang, ¹Nan Xiang, ¹Xiaojuan Dai, ¹Li Jin, ¹Xiaomei Li, ¹Jinhui Tao, ²Xiangpei Li. ¹Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui; ²Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei

10.1136/lupus-2019-lsm.260

Background MicroRNAs play vital role in the immunopathogenesis of human and experimental lupus nephritis, but the contributions of miR-326 to renal injury in systemic lupus erythematosus (SLE) remain to be demonstrated. Here we characterize the function of the miR-326 in MRL/lpr mice of lupus nephritis.

Methods We generated MRL/lpr mice overexpression or silence in miR-326 and analyzed the clinical course of the nephritis with respect to albuminuria. In addition, renal Th17/Treg cells and IL-17A/TGF- expression were detected by flow cytometry and immune-histochemistry respectively.

Results miR-326 overexpression did increase the development of albuminuria in MRL/lpr mice. In contrast, miR-326 silence decreased the development of albuminuria. The characterization of renal CD4 +T cells in miR-326 overexpression mice revealed high numbers of infiltrating Th17 cells and low numbers of infiltrating Tregs. IL-17A and TGF- expression respectively increased and decreased in miR-326 overexpression mice.

Conclusions miR-326 overexpression plays major role in the immunopathogenesis of lupus nephritis in MRL/lpr mice. Thus, our results suggest that miR-326 may be an intriguing new therapeutic approach for patients with lupus nephritis.

Funding Source(s): the National Natural Science Foundation of China 81373186

261

MIR-326 REGULATES CD4+T CELLS DIFFERENTIATION IN LUPUS DISEASE OF MRL/LPR MICE

¹Yuan Xia*, ¹Xuan Fang, ¹Nan Xiang, ¹Xiaojuan Dai, ¹Li Jin, ¹Xiaomei Li, ²Jinhui Tao, ³Xiangpei Li. ¹Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China; ²Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui; ³Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei

10.1136/lupus-2019-lsm.261

Background CD4 +T cells play a major role in systemic lupus erythematosus (SLE). Many aberrations in miR-326 expression have been described as related to abnormal T cell activation in SLE. The aim of this study was to investigate the effect of miR-326 expression on the differentiation of CD4 +T cells in MRL/lpr mice.

Methods 3 groups of female MRL/lpr mice were injected with lentivirus-miR-326 (LV-326) or lentivirus-miR-326 specific inhibitor (LV-sponge) to increase or inhibit miR-326 expression, respectively, and lentivirus-no-encoding (LV-ctrl) as control 10 mice per group. The percentage of Th17, Th1, and Treg cells in spleen were determined by flow cytometry, the expression levels of CD4 +T related cytokines were determined by CBA and ELISA.

Results The results showed that, compared with LV-ctrl mice and LV-sponge mice, LV-326 mice had higher percentage of Th17 cells, and lower percentage of Tregs and Th1 cells in splenic CD4 +T cells. In contrast, LV-sponge mice had lower percentage of Th17 cells as well as higher percentage of Tregs and Th1 cells than LV-ctrl mice in splenic CD4 +T cells. Moreover, serum levels of IL-17A were significantly increased in LV-326 mice, compared with LV-ctrl mice and LV-sponge mice. Serum levels of IL-2 and TGF- were decreased in LV-326 mice compared with LV-ctrl mice.

Conclusions These findings suggesting that miR-326 regulates CD4 +T cells differentiation and inflammatory-related cytokines production in lupus model mouse. Implying that miR-326 may play a vital role in SLE pathogenesis by regulating CD4 +T cells differentiation.

Funding Source(s): the National Natural Science Foundation of China (81373186)

262

IMMUNOLOGICAL PATHWAYS IN SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE MANIFESTATION: CEREBRAL LUPUS

¹Nicole L Fewings*, ²Sanjay Swaminathan, ³David Booth, ⁴Ming Wei Lin. ¹Westmead Institute for Medical Research; ²Department of Clinical Immunology, Westmead Hospital, Sydney, New South Wales, Australia Department of Medicine, University of Sydney, Sydney, New South Wales, Australia Department of Medicine, Western Sydney University, Sydney, New South Wales; ³Centre for Immunology and Allergy Research, Westmead Institute for Medical Research, University of Sydney, Westmead NSW, Australia; ⁴Dept of Clinical Immunology and Immunopathology, Westmead Hospital, Westmead NSW 2145; and Faculty of Medicine, Sydney Medical School, University of Sydney, NSW 2000

10.1136/lupus-2019-lsm.262